CLINICAL CHARACTERISTICS AND FACTORS ASSOCIATED WITH METASTASIS AMONG BREAST CANCER PATIENTS AT CA MAU GENERAL HOSPITAL FROM 2022 TO 2024

Huynh Ngoc Linh1, Chau Tan Dat2, Lam Thanh Hoa2
1 Ca Mau Medical College
2 Ca Mau General Hospital

Main Article Content

Abstract

Objective: To determine the prevalence of metastasis and analyze factors associated with metastatic status among breast cancer patients treated at Ca Mau General Hospital from 2022 to 2024.


Subjects and Methods: A retrospective cross-sectional study was conducted on 579 histologically confirmed breast cancer patients with immunohistochemistry results. Metastatic status was analyzed using logistic regression.


Results: The prevalence of metastasis was 21.76%. The most common metastatic sites were lung (34.13%), bone (33.33%), and liver (29.37%). Multivariable analysis showed that triple-negative subtype (aOR = 4.08; 95%CI: 2.12-7.86), HER2-enriched subtype (aOR = 2.21; 95%CI: 1.18-4.13), histological grade 3 (aOR = 3.97; 95%CI: 1.74-9.05), grade 2 (aOR = 2.41; 95%CI: 1.09-5.31), longer disease duration (trend aOR = 1.89; 95%CI: 1.22-2.93), and right-sided breast cancer (aOR = 1.41; 95%CI: 1.01-2.12) were associated with metastatic status.


Conclusion: The prevalence of metastasis among breast cancer patients in this study was 21.76%. Molecular subtype, histological grade, and disease duration were factors associated with metastatic status. Comprehensive assessment of histopathological and molecular characteristics is important for guiding monitoring and management of breast cancer patients.

Article Details

References

[1]. World Health Organization. Breast cancer [Internet]. Geneva: World Health Organization; 2025 [cited 2026 Apr 9]. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer
[2]. International Agency for Research on Cancer. Breast fact sheet: Globocan 2022 [Internet]. Lyon: International Agency for Research on Cancer; 2024 [cited 2026 Apr 9]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/20-breast-fact-sheet.pdf
[3]. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271-7.
[4]. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
[5]. Weiss A, Chavez-MacGregor M, Lichtensztajn DY, Yi M, Tadros A, Hortobagyi GN, et al. Patterns of distant metastasis in metastatic breast cancer subtypes. Breast Cancer Res. 2018;20(1):78.
[6]. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66.
[7]. Al Saad S, Al Awadhi A, Al Kandari A, Al Hamad M, Al Qoud A, Alfoudri H, et al. Is laterality in breast cancer still worth studying? Local experience from Bahrain. BMC Cancer. 2022;22:968.
[8]. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403-10.